The new medication for Parkinson shows that it is effective in clinical trials: “Very encouraged”

A new medicine has proven promising to combat Parkinson’s disease while minimizing unwanted side effects.

It was discovered that the daily pill, Tavapadon, relieves the symptoms, including stiffness, coordination, tremors and movement, for a longer period of time for patients who also took at least 400 mg of Levodopa per day and were experiencing “motor fluctuations”, which are periods of time when the medication disappears and the return of the symptoms, according to the study.

Until now, Levodopa has been the standard first -line treatment for Parkinson’s patients.

Parkinson’s cases could be doubled worldwide by 2050, the study reveals

Levodopa, which becomes dopamine in the brain and is directed to dopamine D2/d3/d4 receptors, has been related to side effects that include sleep disorders, hallucinations, behavioral disorders of impulse control, weight gain, leg swelling and blood pressure changes, according to researchers.

In the study, Tavapadon, which works by imitating dopamine and aimed at D1/D5 receptors, has the same benefits as Levodopa without adverse effects, according to Hubert H. Fernández, MD, main author of the study and director of the Neurological Restoration Center in Cleveland Clinic.

The dance facilitates the symptoms of depression in Parkinson’s patients, suggests a new study

“It provides patients with another option to relieve their motor fluctuations that are commonly experienced with Levodopa (the best medication we have so far in Parkinson) in the moderate to advanced stages of the disorder,” Fernández told News Digital.

“This global, multiple and fundamental fundamental trial showed that patients placed in Tavapadon had significantly more ‘in time’ and less ‘discount’ compared to those who received placebo, and that the medication was well tolerated by patients.”

In the study, the researchers measured the disorders of patient impulse control, excessive diurnal drowsiness, changes in blood pressure and weight changes, and discovered that the adverse effects linked to Tavapadon were not different from those who received a placebo.

“Of course, this is a short -term study, and we must wait for our long -term study to be really sure that our preliminary observations are still true,” said Fernández. “However, we are very encouraged.”

“Regardless of when used, either in the beginning or as a complementary therapy for Levodopa, we believe it is a general gain.”

The researchers presented the results of the tempo 3 essay at the American Academy of Neurology (AAN) earlier this month in San Diego.

For those who were recently diagnosed and have less serious motor symptoms, Fernández suggested that a dose of Tavapadon once a day could replace the levodopa dose three times a day.

“If they require Levodopa at some point, they will need a lower dose and less frequency, which then reduces their probability of developing motor fluctuations and disclines and other side effects,” he said in a press release.

For those with more advanced Parkinson, Tavapadon could match Levodopa.

Amid the Parkinson’s diagnosis of Brett Favre, the neurologist analyzes how the risk of brain shocks impact

“Then, regardless of when used, either in the beginning or as a therapy attached to the Levodopa, we believe it is a general gain,” Fernández added.

Recent research has found that Parkinson’s cases are expected to increase by 2050, which affect up to 25 million people worldwide.

The greatest increase will affect people over 80, with cases in that age group that are projected to increase by 196% by 2050, they said.

As the results of the long -term trial are pending, ABBVIE, the Tavapadon manufacturer, will soon submit a request to the Food and Medicines Administration for its approval of the medication.

“The FDA will review the application; from there, it can approve it for use, ask more questions that may not be clear or request another study or an extension to verify some results,” said Fernández.

Click here to get the News application

“We hope that this new generation of dopamine agonist, being more selective in its stimulation of the dopamine receptor, and given only once a day, it will be a significant improvement in the symptomatic treatment of the symptoms of EP in the early, medium and advanced diseases of the disease,” he added.

Click here to register in our health newsletter

Dr. Mary Ann Picone, medical director of the MS Center in Holy Name Medical Center in Teaneck, New Jersey, did not participate in the study, but described the results as “very interesting and encouraging as a new tool to improve the quality of life of patients with Parkinson’s disease.”

Recent research has found that Parkinson’s cases are expected to increase by 2050, which affect up to 25 million people worldwide.

“One of the main limitations of long -term use of dopamine is wear phenomena and the need to dose it more frequently,” Picone told News Digital.

“The use of dopamine agonists helps prolong the long -term benefit of dopamine. The decreased benefit of dopamine can lead to ‘freezing’ or episodes where patients have greater rigidity and difficulty moving.”

For more health articles, visit www.Newsnews.com/health

“This new therapy would go to different receptors and allow more ‘on’ time, but without involuntary dyskinesia (not controlled movements) that … can interfere with the function.”